We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
Read MoreHide Full Article
Key Takeaways
SOLV secures FDA clearance to combine Restrata Matrix with V.A.C. Therapy for advanced wound care.
Solventum's combined therapy may reduce dressing changes, streamline workflows and support broader adoption.
SOLV's integrated wound care approach may boost product utilization, recurring demand and incremental revenue.
Solventum Corporation (SOLV - Free Report) recently received FDA 510(k) clearance for the combined use of its Restrata Synthetic Electrospun Fiber Matrix and V.A.C. Therapy, marking a significant step in advancing its wound care portfolio. The clearance brings together two complementary technologies to support wound healing and reflects the company’s continued focus on developing innovative solutions for complex wounds.
The regulatory milestone is likely to strengthen SOLV’s competitive position in the advanced wound care market by expanding the clinical applications of its existing technologies and creating opportunities to drive broader adoption. The combined offering could also support more efficient wound management and improve care team workflows, potentially contributing to long-term growth. However, the commercial impact will depend on market adoption and the company’s ability to translate this innovation into incremental revenue.
SOLV Stock Trend Following the News
Following the announcement on Oct. 20, SOLV stock has traded flat till yesterday’s closing. Year to date, shares of the company have gained 10.4% compared with the industry’s 9.7% growth and the S&P 500’s 12.7% rise.
The FDA clearance may support SOLV’s long-term growth by strengthening its position in the advanced wound care market and expanding the clinical utility of its existing portfolio. By combining Restrata Matrix with V.A.C. Therapy, the company can offer clinicians an integrated approach to managing complex wounds, potentially encouraging broader adoption of both products. The combination may also help reduce dressing changes and streamline care workflows, enhancing its value proposition for healthcare providers. Over time, increased utilization could support recurring product demand, deepen customer relationships and create opportunities for incremental revenue growth.
SOLV currently has a market capitalization of $14.75 billion.
Image Source: Zacks Investment Research
More on the News
Solventum's FDA clearance covers the combined use of Restrata Matrix and V.A.C. Therapy, bringing together two complementary technologies designed to support different aspects of wound healing. Restrata Matrix, acquired through Solventum's acquisition of Acera Surgical in December 2025, is a fully synthetic, resorbable matrix designed to support soft tissue repair. Rather than relying on growth factors, it provides structural cues that facilitate cellular infiltration, new blood vessel formation and organized collagen deposition. The matrix is also designed to withstand challenging wound environments and resist enzymatic degradation, gradually breaking down through hydrolysis and leaving native tissue behind.
V.A.C. Therapy complements the matrix by using negative pressure wound therapy to create a healing-conducive environment. When used with compatible dressings, the therapy helps maintain close contact between Restrata Matrix and the wound bed. Its macrostrain mechanism draws wound edges together, while microstrain stimulates cell proliferation, angiogenesis and granulation tissue formation. The therapy also promotes blood flow, reduces swelling and removes fluid and infectious material. Solventum's V.A.C. Peel and Place Dressing supports wear time of up to seven days per application, aligning with Restrata Matrix's resistance to enzymatic degradation.
The combined approach is designed to address both tissue repair and wound environment management, particularly in complex wound cases. Unlike many collagen-based matrices that may degrade prematurely, Restrata's synthetic composition supports its use alongside V.A.C. Therapy throughout the dressing wear period. This compatibility may reduce dressing changes, minimize disruptions to the healing process, and give care teams a more predictable treatment workflow. Solventum highlighted clinician feedback indicating that Restrata Matrix can support granulation tissue growth within days in challenging wounds, although the company did not disclose quantified clinical outcomes or projected revenue from the newly cleared combination.
The clearance builds on the company's December 2025 acquisition of Acera Surgical and supports its strategy of integrating advanced wound care technologies into a broader portfolio.
Industry Prospects Favoring the Market
According to data provided by MarketsandMarkets, the global advanced wound care market is projected to reach $19.32 billion by 2030 from $13.37 billion in 2025, at a CAGR of 7.6 %.
The advanced wound care market is driven by the growing geriatric population, the rising prevalence of chronic diseases and an increase in traumatic injuries and burn cases. These factors are driving demand for effective wound management solutions, while supportive government initiatives and favorable reimbursement frameworks further fuel market growth.
Other News
In August, SOLV announced plans to separate its Health Information Systems (HIS) business to sharpen its focus on its core MedSurg and Dental Solutions segments. The move could unlock shareholder value by enabling more targeted capital allocation, while HIS, which generates $1.4 billion in annual sales and serves more than 75% of U.S. hospitals, may benefit from greater strategic flexibility. However, execution risks and uncertainty surrounding the transaction structure remain key concerns.
SOLV’s Zacks Rank & Key Picks
Currently, SOLV carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.
View the Zacks #1 Rank List
Image: Bigstock
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
Key Takeaways
Solventum Corporation (SOLV - Free Report) recently received FDA 510(k) clearance for the combined use of its Restrata Synthetic Electrospun Fiber Matrix and V.A.C. Therapy, marking a significant step in advancing its wound care portfolio. The clearance brings together two complementary technologies to support wound healing and reflects the company’s continued focus on developing innovative solutions for complex wounds.
The regulatory milestone is likely to strengthen SOLV’s competitive position in the advanced wound care market by expanding the clinical applications of its existing technologies and creating opportunities to drive broader adoption. The combined offering could also support more efficient wound management and improve care team workflows, potentially contributing to long-term growth. However, the commercial impact will depend on market adoption and the company’s ability to translate this innovation into incremental revenue.
SOLV Stock Trend Following the News
Following the announcement on Oct. 20, SOLV stock has traded flat till yesterday’s closing. Year to date, shares of the company have gained 10.4% compared with the industry’s 9.7% growth and the S&P 500’s 12.7% rise.
The FDA clearance may support SOLV’s long-term growth by strengthening its position in the advanced wound care market and expanding the clinical utility of its existing portfolio. By combining Restrata Matrix with V.A.C. Therapy, the company can offer clinicians an integrated approach to managing complex wounds, potentially encouraging broader adoption of both products. The combination may also help reduce dressing changes and streamline care workflows, enhancing its value proposition for healthcare providers. Over time, increased utilization could support recurring product demand, deepen customer relationships and create opportunities for incremental revenue growth.
SOLV currently has a market capitalization of $14.75 billion.
Image Source: Zacks Investment Research
More on the News
Solventum's FDA clearance covers the combined use of Restrata Matrix and V.A.C. Therapy, bringing together two complementary technologies designed to support different aspects of wound healing. Restrata Matrix, acquired through Solventum's acquisition of Acera Surgical in December 2025, is a fully synthetic, resorbable matrix designed to support soft tissue repair. Rather than relying on growth factors, it provides structural cues that facilitate cellular infiltration, new blood vessel formation and organized collagen deposition. The matrix is also designed to withstand challenging wound environments and resist enzymatic degradation, gradually breaking down through hydrolysis and leaving native tissue behind.
V.A.C. Therapy complements the matrix by using negative pressure wound therapy to create a healing-conducive environment. When used with compatible dressings, the therapy helps maintain close contact between Restrata Matrix and the wound bed. Its macrostrain mechanism draws wound edges together, while microstrain stimulates cell proliferation, angiogenesis and granulation tissue formation. The therapy also promotes blood flow, reduces swelling and removes fluid and infectious material. Solventum's V.A.C. Peel and Place Dressing supports wear time of up to seven days per application, aligning with Restrata Matrix's resistance to enzymatic degradation.
The combined approach is designed to address both tissue repair and wound environment management, particularly in complex wound cases. Unlike many collagen-based matrices that may degrade prematurely, Restrata's synthetic composition supports its use alongside V.A.C. Therapy throughout the dressing wear period. This compatibility may reduce dressing changes, minimize disruptions to the healing process, and give care teams a more predictable treatment workflow. Solventum highlighted clinician feedback indicating that Restrata Matrix can support granulation tissue growth within days in challenging wounds, although the company did not disclose quantified clinical outcomes or projected revenue from the newly cleared combination.
The clearance builds on the company's December 2025 acquisition of Acera Surgical and supports its strategy of integrating advanced wound care technologies into a broader portfolio.
Industry Prospects Favoring the Market
According to data provided by MarketsandMarkets, the global advanced wound care market is projected to reach $19.32 billion by 2030 from $13.37 billion in 2025, at a CAGR of 7.6 %.
The advanced wound care market is driven by the growing geriatric population, the rising prevalence of chronic diseases and an increase in traumatic injuries and burn cases. These factors are driving demand for effective wound management solutions, while supportive government initiatives and favorable reimbursement frameworks further fuel market growth.
Other News
In August, SOLV announced plans to separate its Health Information Systems (HIS) business to sharpen its focus on its core MedSurg and Dental Solutions segments. The move could unlock shareholder value by enabling more targeted capital allocation, while HIS, which generates $1.4 billion in annual sales and serves more than 75% of U.S. hospitals, may benefit from greater strategic flexibility. However, execution risks and uncertainty surrounding the transaction structure remain key concerns.
SOLV’s Zacks Rank & Key Picks
Currently, SOLV carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.